The role of chemotherapy and adjuvant therapy in the management of breast cancer in older women

Cancer

Volumn 74, Issue 7 S, 1994, Pages 2165-2171

  Muss, Hyman B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

adjuvant therapy; aging; breast cancer; chemotherapy; elderly; endocrine therapy

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANTIESTROGEN; CARBOPLATIN; CATHEPSIN D; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; ESTROGEN; ESTROGEN RECEPTOR; FLUOROURACIL; FLUOXYMESTERONE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEGESTROL; MELPHALAN; METHOTREXATE; MITOMYCIN; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; PROGESTERONE; PROGESTERONE RECEPTOR; PROTEIN P53; TAMOXIFEN; THIOTEPA; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

AGED; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MASTECTOMY; META ANALYSIS; METASTASIS; NEPHROTOXICITY; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TUMOR VOLUME;

AGED; AGING; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL RATE; TAMOXIFEN;

EID: 0028093508     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(19941001)74:7+<2165::AID-CNCR2820741727>3.0.CO;2-6     Document Type: Article

References (34)

1. Breast cancer in aging women: a population‐based study of contrasts in stage, surgery, and survival
2. Cancer statistics, 1993
3. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women
4. Survival and prognostic factors in node‐negative breast cancer: results of long‐term followup studies
5. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer
6. Prognostic factors and treatment decisions in axillary‐node‐negative breast cancer
7. Prolonging tamoxifen therapy for primary breast cancer. Findings from the National Surgical Adjuvant Breast and Bowel Project clinical trial
8. Long‐term tamoxifen adjuvant therapy in node‐positive breast cancer: a metabolic and pilot clinical study
9. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh
10. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node‐negative breast cancer who have estrogen‐receptor‐negative tumors
11. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer: a double‐blind comparison with placebo
12. Tamoxifen versus placebo: double‐blind adjuvant trial in elderly women with stage II breast cancer
13. Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. International Breast Cancer Study Group
14. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer
15. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial
16. Cardiac and thromboembolic morbidity among postmenopausal women with early‐stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group
17. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
18. Adjuvant chemotherapy in older women with node positive breast cancer: the Piedmont Oncology Association experience [abstract]
19. Recombinant hemopoietic growth factors (rHGF) may protect older patients from chemotherapy myelodepression [abstract]
20. Should the elderly receive chemotherapy for node‐negative breast cancer? A costeffectiveness analysis examining total and active life‐expectancy outcomes
21. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more
22. Preoperative chemotherapy is beneficial for geriatric patients with locally advanced and metastatic breast cancer
23. Mastectomy or tamoxifen as initial therapy for operable breast cancer in elderly patients: 5‐year follow‐up
24. Endocrine therapy for advanced breast cancer: a review
25. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers
26. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women
27. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia
28. A study of excess hematologic toxicity in elderly patients treated on chemotherapy protocols
29. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group
30. Cyclophosphamide, methotrexate, and 5‐fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance
31. Chemical and hormonal therapies in the elderly [review]
32. Cancer chemotherapy in the elderly: clinical pharmacologic considerations
33. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [comment]
34. Psychosocial consequences of cancer chemotherapy for elderly patients